Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945513 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles
A Phase 3 study of Contraception, sponsored by Insud Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,034
- Enrollment target
- 1
- Study location
NCT03945513 is a Phase 3 study of Contraception that has completed, run by Insud Pharma. The registered enrollment target is 1,034 participants, above the 440-participant average among 72 other Contraception trials with a reported enrollment target (135% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03945513, a Phase 3 study of Contraception, has completed, sponsored by Insud Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,034 participants
- Enrollment target
- 1
- Study location
Study Summary
The main objective of this trial is to demonstrate the contraceptive efficacy of LPRI424, Additional goals of the trial are to demonstrate the safety and tolerability of LPRI424.
Conditions Studied
Interventions
- DRUG LPRI424 (dienogest/ethinylestradiol)
Study Locations (1)
Georgia
- Fellows Research Alliance, Inc. - Savannah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,034 participants |
| Start Date | 2019-12-03 |
| Est. Completion | 2023-09-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03945513
The ClinicalTrials.gov registry entry for NCT03945513 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,034 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 440-participant average among 72 other Contraception trials with a reported enrollment target (135% higher). The listed sponsor is Insud Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contraception appearing as the primary indexed condition, and to 1 intervention - of which LPRI424 (dienogest/ethinylestradiol) is the first listed.
NCT03945513 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03945513 about?
NCT03945513 is a clinical study titled "A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles". The main objective of this trial is to demonstrate the contraceptive efficacy of LPRI424, Additional goals of the trial are to demonstrate the safety and tolerability of LPRI424.
What is the current status of trial NCT03945513?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,034 participants. The study started on 2019-12-03. Estimated completion is 2023-09-08.
What conditions does trial NCT03945513 study?
This clinical trial studies the following conditions: Contraception.
What interventions are being tested in trial NCT03945513?
The interventions under investigation include: LPRI424 (dienogest/ethinylestradiol) (DRUG).
Who is sponsoring clinical trial NCT03945513?
This trial is sponsored by Insud Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03945513 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraception
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
ACTIVE NOT RECRUITING · Phase 3
-
A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.
COMPLETED · Phase 3
-
Study of Safety and Efficacy of an Oral Contraceptive
COMPLETED · Phase 3
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Intravenous Ketorolac Administration to Attenuate Post-procedural Pain Associated With Intrauterine Device Placement
RECRUITING · Phase 4
-
Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.